Literature DB >> 18307994

Enhanced binding of TBK1 by an optineurin mutant that causes a familial form of primary open angle glaucoma.

Simon Morton1, Luke Hesson, Mark Peggie, Philip Cohen.   

Abstract

TANK-binding kinase 1 (TBK1) was identified as a binding partner for Optineurin (OPTN) in two-hybrid screens, an interaction confirmed by overexpression/immunoprecipitation experiments in HEK293 cells and by coimmunoprecipitation of endogenous OPTN and TBK1 from cell extracts. A TBK1 binding site was located between residues 1-127 of OPTN, residues 78-121 displaying striking homology to the TBK1-binding domain of TANK. The OPTN-binding domain was localised to residues 601-729 of TBK1, while TBK1[1-688] which cannot bind to TANK, did not interact with OPTN. The OPTN[E50K] mutant associated with Primary Open Angle Glaucoma (POAG) displayed strikingly enhanced binding to TBK1, suggesting that this interaction may contribute to familial POAG caused by this mutation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18307994     DOI: 10.1016/j.febslet.2008.02.047

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  91 in total

Review 1.  Cellular and molecular biology of optineurin.

Authors:  Hongyu Ying; Beatrice Y J T Yue
Journal:  Int Rev Cell Mol Biol       Date:  2012       Impact factor: 6.813

2.  Confirmation of TBK1 duplication in normal tension glaucoma.

Authors:  Kazuhide Kawase; R Rand Allingham; Akira Meguro; Nobuhisa Mizuki; Ben Roos; Frances M Solivan-Timpe; Alan L Robin; Robert Ritch; John H Fingert
Journal:  Exp Eye Res       Date:  2012-01-02       Impact factor: 3.467

3.  Optineurin, a multifunctional protein involved in glaucoma, amyotrophic lateral sclerosis and antiviral signalling.

Authors:  Ghanshyam Swarup; Ananthamurthy Nagabhushana
Journal:  J Biosci       Date:  2010-12       Impact factor: 1.826

Review 4.  Primary open-angle glaucoma genes.

Authors:  J H Fingert
Journal:  Eye (Lond)       Date:  2011-05       Impact factor: 3.775

5.  Structural insights into the ubiquitin recognition by OPTN (optineurin) and its regulation by TBK1-mediated phosphorylation.

Authors:  Faxiang Li; Daichao Xu; Yingli Wang; Zixuan Zhou; Jianping Liu; Shichen Hu; Yukang Gong; Junying Yuan; Lifeng Pan
Journal:  Autophagy       Date:  2018-02-02       Impact factor: 16.016

6.  Mutations in the ubiquitin-binding domain of OPTN/optineurin interfere with autophagy-mediated degradation of misfolded proteins by a dominant-negative mechanism.

Authors:  Wen-Chuan Shen; Huei-Ying Li; Guang-Chao Chen; Yijuang Chern; Pang-Hsien Tu
Journal:  Autophagy       Date:  2015-04-03       Impact factor: 16.016

7.  Structure and ubiquitination-dependent activation of TANK-binding kinase 1.

Authors:  Daqi Tu; Zehua Zhu; Alicia Y Zhou; Cai-hong Yun; Kyung-Eun Lee; Angela V Toms; Yiqun Li; Gavin P Dunn; Edmond Chan; Tran Thai; Shenghong Yang; Scott B Ficarro; Jarrod A Marto; Hyesung Jeon; William C Hahn; David A Barbie; Michael J Eck
Journal:  Cell Rep       Date:  2013-02-28       Impact factor: 9.423

8.  TBK1 and flanking genes in human retina.

Authors:  John H Fingert; Benjamin W Darbro; Qining Qian; Richard Van Rheeden; Kathy Miller; Megan Riker; Frances Solivan-Timpe; Ben R Roos; Alan L Robin; Robert F Mullins
Journal:  Ophthalmic Genet       Date:  2013-02-20       Impact factor: 1.803

9.  Optineurin negatively regulates the induction of IFNbeta in response to RNA virus infection.

Authors:  Jamel Mankouri; Rennos Fragkoudis; Kathryn H Richards; Laura F Wetherill; Mark Harris; Alain Kohl; Richard M Elliott; Andrew Macdonald
Journal:  PLoS Pathog       Date:  2010-02-19       Impact factor: 6.823

10.  Optineurin coding variants in Ghanaian patients with primary open-angle glaucoma.

Authors:  Yutao Liu; Stephen Akafo; Cecile Santiago-Turla; Claudia S Cohen; Karen R Larocque-Abramson; Xuejun Qin; Leon W Herndon; Pratap Challa; Silke Schmidt; Michael A Hauser; R Rand Allingham
Journal:  Mol Vis       Date:  2008-12-18       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.